PF-Atlas › Clinical Trials › NCT03056989

A Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis

SPX-101 · Phase 1

Registry ID

NCT03056989

Phase

Phase 1

Status

Completed

Drug / intervention

SPX-101

Sponsor

Spyryx Biosciences, Inc.

Start

2017-05-31

Enrollment

Locations

About this trial

Ascending dose, 7-day, open label safety trial of SPX-101 Inhalation Solution in adult subjects with cystic fibrosis.

View NCT03056989 on ClinicalTrials.gov →

Explore related

All SPX-101 trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT03056989 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.